OSE Immunotherapeutics — Lusvertikimab impresses in extension period data
OSE Immunotherapeutics has presented new data for lusvertikimab in ulcerative colitis (UC), with encouraging results from the extension period of...
308 Views
OSE Immunotherapeutics — Primed for value appreciation
OSE Immunotherapeutics is a clinical-stage immuno-oncology and immuno-inflammation company, with a pipeline spanning all stages of development. The...
285 Views
OSE Immunotherapeutics — KOL event highlights lusvertikimab’s potential
OSE Immunotherapeutics and Edison held a key opinion leader (KOL) event on 5 March 2025, providing up-to-date insights into OSE’s lead...
109 Views
OSE Immunotherapeutics — Tedopi shows promise in pancreatic cancer
OSE Immunotherapeutics has reported positive top-line data from the investigator-sponsored Phase II trial assessing Tedopi in combination with...
141 Views
OSE Immunotherapeutics - Full Lusvertikimab results reflect potential in UC
OSE Immunotherapeutics’ final analysis of the CoTikiS trial in ulcerative colitis (UC) confirmed that Lusvertikimab met the primary endpoint with...
427 Views